Compare GXAI & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | ACON |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.0M |
| IPO Year | 2022 | 2022 |
| Metric | GXAI | ACON |
|---|---|---|
| Price | $0.40 | $1.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.5K | 16.2K |
| Earning Date | 11-20-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 71.35 | ★ 99.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,933,030.00 | $75,730.00 |
| Revenue This Year | $462.16 | $44.55 |
| Revenue Next Year | $30.00 | $123.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | 65.62 |
| 52 Week Low | $0.41 | $1.71 |
| 52 Week High | $5.26 | $9.36 |
| Indicator | GXAI | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 31.46 |
| Support Level | N/A | N/A |
| Resistance Level | $0.52 | $2.06 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.02 | 20.54 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.